{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-001345","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.539257+00:00","generated_at":"2026-06-27T02:47:21.250427+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"PharmaCyte Biotech receives Nasdaq board independence deficiency notice after director death","bullets":["Independent director Thomas C.K. Yuen passed away Feb 13, 2022, triggering noncompliance with Nasdaq Listing Rule 5605(b)(1).","Cure period: until earlier of next annual shareholders' meeting or Feb 13, 2023; if meeting before Aug 12, 2022, compliance by Aug 12, 2022.","Company expects to appoint a new independent director to regain compliance before the cure period expires."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-001345","json":"https://secwatch.observer/filing/0001683168-22-001345.json","markdown":"https://secwatch.observer/filing/0001683168-22-001345.md","text":"https://secwatch.observer/filing/0001683168-22-001345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822001345/0001683168-22-001345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822001345/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:47:21.250427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}